Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf the number on the scales hasn't moved the way you expected, you're not alone. Most people do lose weight on tirzepatide, but the pace varies considerably, and several real, fixable factors can slow or stall progress. This page walks through the most common reasons, in the order they tend to matter, using evidence from the SURMOUNT-1 trial published in the New England Journal of Medicine and NHS guidance on tirzepatide. Tirzepatide is a prescription-only medicine; a prescriber assesses whether it's clinically suitable for you, and the same prescriber can review what's happening if your results feel disappointing.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first thing worth understanding is that tirzepatide is designed to be started low and increased gradually. Treatment begins at 2.5 mg, a dose whose main job is helping your body adjust rather than delivering maximum weight loss. Most people won't see dramatic results at this stage, and that's expected. The dose is typically raised in 4-week steps by your prescriber, working up through 5 mg, 7.5 mg, 10 mg, 12.5 mg and potentially 15 mg.
In SURMOUNT-1, average weight reductions of around 20–21% were recorded at 15 mg over 72 weeks. That figure comes from participants who spent most of the trial at their maintenance dose, not the starting one. If you've been on tirzepatide for only a few weeks, comparing your results to trial endpoints is comparing the beginning of a process to its conclusion.
If you're unsure how your current dose fits into the broader picture of what weight loss on tirzepatide typically looks like, or you want to understand the expected timeline, it's worth reviewing that with your prescriber rather than assuming the medicine isn't working.
Patience at this stage isn't passive. It's part of the clinical plan.
Tirzepatide reduces appetite. It does not make calorie intake irrelevant. One of the most common reasons people plateau or stall is that, as the initial nausea and appetite suppression settle, food intake gradually edges back up without anyone noticing.
This is especially easy to miss with liquids. Fizzy drinks, fruit juices, alcohol, and even oat-milk lattes carry significant calories and don't trigger the same fullness signals that solid food does. A useful question to ask yourself: has what you're drinking changed since you started treatment?
On the food side, protein adequacy matters more than many people expect. When the body loses weight quickly, it can lose muscle alongside fat. Getting enough protein, alongside some resistance-based activity, helps protect lean mass and keeps metabolism from falling more than it needs to. The NHS healthy weight guidance is a practical starting point for thinking about diet quality alongside treatment.
None of this means counting every calorie obsessively. But a quiet audit, even just for a week, can reveal patterns that are easy to overlook.
Biology isn't purely about what you eat. Several factors outside diet and dose can meaningfully slow weight loss on tirzepatide, and they're worth raising with your prescriber rather than waiting out in silence.
Sleep is one. Consistently poor sleep raises levels of cortisol and ghrelin, a hunger hormone, and blunts the satiety signals that tirzepatide is partly designed to amplify. Stress works similarly. Neither is a character flaw; both are physiological variables your prescriber should know about.
Thyroid function is another. An underactive thyroid slows metabolism and can substantially offset the effects of any weight-loss treatment. If you haven't had thyroid levels checked recently, it's a reasonable question to raise.
Some medications can also interfere with weight loss, including certain antidepressants, antipsychotics, and corticosteroids. If your prescription list has changed since starting tirzepatide, that's relevant clinical information.
There's also the question of how long a plateau has actually lasted. A week of flat scales is normal fluctuation, partly driven by water retention. A genuine plateau of six or more weeks at your current dose may warrant a clinical review of whether a dose increase is appropriate. Our clinical team has written more about how long Mounjaro typically takes to work, which gives useful context here.
Most stalls have a fixable cause. But there's a point at which a brief self-review isn't enough, and what's needed is an actual clinical conversation about your specific situation.
If you've been at your current dose for at least six weeks, your diet and sleep haven't meaningfully changed, and the scales have genuinely not moved, that's worth discussing with your prescriber. It may prompt a dose review, a check on any underlying conditions, or a look at what else might be at play. The full guide to not losing weight on tirzepatide covers this territory in more depth, including what questions to bring to that conversation. If you are specifically using Mounjaro and want targeted advice, our guides on being on Mounjaro and not losing weight and not losing weight on Mounjaro explore the most common reasons this happens and what you can do about it.
A few people find it helpful to remember that cost is often a concern at this stage too: if treatment doesn't feel like it's working, the natural reaction is to wonder whether to keep paying for it. The Mounjaro pricing context page sets out what transparent, all-in private treatment costs cover, which can help frame that decision clearly.
If you're looking at starting treatment, or restarting after a break, our prescribers review every consultation personally, and the same review happens before every repeat order. You can start a free consultation to speak to our clinical team about your situation directly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.